Trovagene inks deal with unnamed biopharma firm for ctDNA tests; shares ahead 32% premarket

|By:, SA News Editor

Nano cap Trovagene (NASDAQ:TROV) jumps 32% premarket on increased volume in response to its announcement that it has entered into an agreement with a global biopharma company to provide Trovera urine circulating tumor DNA (ctDNA) biomarker tests and services for use in its clinical trials.

Financial terms are not disclosed.

Subscribe for full text news in your inbox